Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P: Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996, 347: 635-9.
Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D: A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993, 329: 1370-6. 10.1056/NEJM199311043291902.
Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F: Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996, 124: 619-26.
Barritt D, Jordan S: Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960, 1: 345-
Weinmann EE, Salzman EW: Deep-vein thrombosis. New Engl J Med. 1994, 331: 1630-41. 10.1056/NEJM199412153312407.
Clagett GP, Anderson FA, Levine MN, Salzman EW, Wheeler HB: Prevention of venous thromboembolism. Chest. 1992, 102: 391S-407S.
Manganelli D, Palla A, Donnamaria V, Giuntini C: Clinical features of pulmonary embolism. Doubts and certainties. Chest. 1995, 107: 25S-32S.
Griffin JH, Evatt B, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993, 82: 1989-93.
Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993, 342: 1503-6.
Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994, 330:5: 17-22.
Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA: Association of idiopathic venous thromboembolism with single point- mutation at Arg506 of factor V. Lancet. 1994, 343: 1535-6. 10.1016/S0140-6736(94)92939-4.
Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995, 85: 1504-8.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990, 86: 1343-6.
Dzau VJ: Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl. 1994, 12: S3-10.
Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B: Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994, 343: 1361-2. 10.1016/S0140-6736(94)92497-X.
Nachman RL, Silverstein R: Hypercoagulable. Ann Intern Med. 1993, 119: 819-27.
Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993, 90: 1004-8.
Dahlback B, Hildebrand B: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA. 1994, 91: 1396-400.
Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, Mannucci PM: Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost. 1999, 81: 879-86.
Svensson PJ, Benoni G, Fredin H, Bjorgell O, Nilsson P, Hedlund U, Nylander G, Bergqvist D, Dahlback B: Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost. 1997, 78: 993-6.
Ryan DH, Crowther MA, Ginsberg JS, Francis CW: Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998, 128: 270-6.
Woolson ST, Zehnder JL, Maloney WJ: Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty. J Arthroplasty. 1998, 13: 207-10.
Philipp CS, Dilley A, Saidi P, Evatt B, Austin H, Zawadsky J, Harwood D, Ellingsen D, Barnhart E, Phillips DJ, Hooper WC: Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost. 1998, 80: 869-73.
Schlesselman J: Case control studies: Design, conduct, analysis. New York: Oxford Press;. 1982